In July 2011, the Medicines Patent Pool (MPP) signed a licence agreement with Gilead Sciences for several antiretrovirals. It included a covenant not to sue on products containing emtricitabine (FTC). FTC is recommended by the World Health Organization (WHO) as a component of first and second-line treatment regimens for adults and children.
In September 2017, the two parties amended the agreement to allow for an extension of the Territory for FTC to Belarus, Malaysia, Ukraine and Philippines. Together, the extended territory is home to 90.5% of people living with HIV in low- and middle-income countries.
In September 2019, the agreement with Gilead Sciences mentioned above was amended to allow for the inclusion of Azerbaijan to the territory of now 117 countries.
See related licence
Click the logos to access the sublicensing agreements:
Sublicence Agreement
Amendment of 9 April 2018
Amendment of 21 November 2019
Amendment of 20 November 2019
Amendment of 27 November 2017
Amendment of 20 November 2017
Amendment of 16 December 2019
Legal
Access to Medicines Tracker
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.